Contributions
Abstract: P412
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Introduction: There is growing evidence that vascular disease risk factors (VDRF), such as hyperlipidemia, hypertension, obesity, diabetes, and heart disease, can significantly increase the risk of disability progression in MS. Recent research has shown MS subjects with one or more VDRF at diagnosis required unilateral assistance to walk at earlier times than those without any VDRF. There also appeared to be a dose-response relationship between VDRF and MS disability with presence of a single VDRF increasing the risk of early gait disability by 51% and presence of 2 of these conditions increasing the risk by 228%.
Objectives: To study how VDRF affect cerebral blood flow and brain metabolism measured by DCE MRI and 31P magnetic resonance spectroscopy and imaging (MRSI) in people with MS.
Methods: This is a 3-year long observational study with a single-site, mixed design (cross sectional and longitudinal) with two arms. The study includes prospective brain MRI and clinical disease progression outcome measurements. MRI data is collected at baseline, 12, 24 and 36 months. We enrolled a total of 60 MS subjects consisting of 35 subjects with VDRF (VDRFP) and 25 subjects without VDRF (VDRFN).
Aims: The outcome measures include changes in the VDRFP and VDRFN groups in the following: 1) cerebral blood flow and blood volume detected by 7T MRI and high energy phosphate metabolites in cerebral gray matter (GM) assessed by 31P 7T magnetic resonance spectroscopic imaging (MRSI), 2) brain atrophy, 3) clinical impairment, disability, and quality of life.
Results: We preformed cross-sectional analyses of baseline data. Average age of the 50 subjects, whose MR data were analyzed, was 54.5 years (SD:7.5); 72% female). 28 subjects have VDRFP (average age 56.4years (SD:6.9); 82% female) and 22 subjects were VDRFN (average age 52.2 years (SD:7.8); 59% female). A volume of interest in parietal brain region was analyzed for changes in phosphate metabolites. Adenosine triphosphate (ATP) to total phosphate signal ratio is decreased in VDRFP subjects by 4.5% (P< 0.05). Brain parenchymal volume (normalized for head size) was assessed using SIENAX [1]. VDRFP female subjects showed a 3.9% decrease in normalized brain tissue (P=0.02, N1=13,N2=23,one-tailed Student's t-test).
Conclusions: Our preliminary results support the view of an impaired metabolic state in VDRFP MS subjects that may potentially increase risk of neurodegeneration.
Disclosure: Vijayshree Yadav: nothing to disclose
Michael Lane: nothing to disclose
Frank Bittner: nothing to disclose
Allison Fryman: nothing to disclose
Manoj Sammi: nothing to disclose
William Rooney: nothing to disclose
Charles Murchison: nothing to disclose
Dennis Bourdette: nothing to disclose
Abstract: P412
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Introduction: There is growing evidence that vascular disease risk factors (VDRF), such as hyperlipidemia, hypertension, obesity, diabetes, and heart disease, can significantly increase the risk of disability progression in MS. Recent research has shown MS subjects with one or more VDRF at diagnosis required unilateral assistance to walk at earlier times than those without any VDRF. There also appeared to be a dose-response relationship between VDRF and MS disability with presence of a single VDRF increasing the risk of early gait disability by 51% and presence of 2 of these conditions increasing the risk by 228%.
Objectives: To study how VDRF affect cerebral blood flow and brain metabolism measured by DCE MRI and 31P magnetic resonance spectroscopy and imaging (MRSI) in people with MS.
Methods: This is a 3-year long observational study with a single-site, mixed design (cross sectional and longitudinal) with two arms. The study includes prospective brain MRI and clinical disease progression outcome measurements. MRI data is collected at baseline, 12, 24 and 36 months. We enrolled a total of 60 MS subjects consisting of 35 subjects with VDRF (VDRFP) and 25 subjects without VDRF (VDRFN).
Aims: The outcome measures include changes in the VDRFP and VDRFN groups in the following: 1) cerebral blood flow and blood volume detected by 7T MRI and high energy phosphate metabolites in cerebral gray matter (GM) assessed by 31P 7T magnetic resonance spectroscopic imaging (MRSI), 2) brain atrophy, 3) clinical impairment, disability, and quality of life.
Results: We preformed cross-sectional analyses of baseline data. Average age of the 50 subjects, whose MR data were analyzed, was 54.5 years (SD:7.5); 72% female). 28 subjects have VDRFP (average age 56.4years (SD:6.9); 82% female) and 22 subjects were VDRFN (average age 52.2 years (SD:7.8); 59% female). A volume of interest in parietal brain region was analyzed for changes in phosphate metabolites. Adenosine triphosphate (ATP) to total phosphate signal ratio is decreased in VDRFP subjects by 4.5% (P< 0.05). Brain parenchymal volume (normalized for head size) was assessed using SIENAX [1]. VDRFP female subjects showed a 3.9% decrease in normalized brain tissue (P=0.02, N1=13,N2=23,one-tailed Student's t-test).
Conclusions: Our preliminary results support the view of an impaired metabolic state in VDRFP MS subjects that may potentially increase risk of neurodegeneration.
Disclosure: Vijayshree Yadav: nothing to disclose
Michael Lane: nothing to disclose
Frank Bittner: nothing to disclose
Allison Fryman: nothing to disclose
Manoj Sammi: nothing to disclose
William Rooney: nothing to disclose
Charles Murchison: nothing to disclose
Dennis Bourdette: nothing to disclose